Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RX-3117 |
Synonyms | |
Therapy Description |
RX-3117 (Fluorocyclopentenylcytosine) is a small molecule that disrupts normal metabolic process, leading to cell death (Journal of Clinical Oncology 35, no. 4_suppl (February 1 2017) 445-445, PMID: 32295203, PMID: 31262886). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RX-3117 | TV-1360|Fluorocyclopentenylcytosine|Roducitabine|RX3117 | RX-3117 (Fluorocyclopentenylcytosine) is a small molecule that disrupts normal metabolic process, leading to cell death (Journal of Clinical Oncology 35, no. 4_suppl (February 1 2017) 445-445, PMID: 32295203, PMID: 31262886). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02030067 | Phase Ib/II | RX-3117 | Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies | Completed | USA | 0 |
NCT03189914 | Phase Ib/II | RX-3117 | RX-3117 in Combination With Abraxane in Subjects With Metastatic Pancreatic Cancer | Completed | USA | 0 |